Lung-specific immune response in tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 4, Issue 2 SUPPL. 1, 2000, Pages

  Condos, R ^a,c   Rom, W N ^a   Weiden, M ^b  

^a NEW YORK UNIVERSITY   (United States)

^b Jaffe Food Allergy Institute   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 8; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR;

CELLULAR IMMUNITY; CONFERENCE PAPER; CYTOKINE PRODUCTION; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFLAMMATION; LUNG; LUNG ALVEOLUS MACROPHAGE; LUNG GRANULOMA; LUNG LAVAGE; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; BRONCHOALVEOLAR LAVAGE FLUID; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTES; MACROPHAGES, ALVEOLAR; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY; VIRUS REPLICATION;

EID: 0034006640     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (61)

1. World Health Organization. Report on the TB epidemic. WHO/TB 94: 177. Geneva: World Health Organization, 1994.
2. New York City Department of Health Bureau of Tuberculosis Control. Information Summary. New York: NYC DOH, 1997.
3. Kaufmann SHE, Flesch I E A. The role of T cell macrophage interactions in tuberculosis. Springer Semin. Immunopathol 1988; 10: 337-358.
4. Boom W H, Husson R N, Young R A, David J R, Piessens W F. In vivo and in vitro characterization of murine t cell clones reactive to Al. tuberculosis. Infect Immun 1987; 55: 2223-2227.
5. Friedland J S. Chemotactic cytokines and tuberculosis. Biochem Soc Trans 1994; 2: 310-312.
6. Munk M E, Emoto M. Functions of T-cell subsets and cytokines in mycobacterial infections. Eur Respir J 1995; 8 (Suppl): 668s-675s.
7. Law K F, Jagirdar J, Weiden M, Bodkin M, Rom W N. Tuberculosis in HIV-positive patients: cellular response and immune activation in the lung. Am J Respir Crit Care Med 1996; 153: 1377-1384.
8. Zhang M, Lin Y, lyer D V, Gong J, Abrams J S, Barnes P F. T-cell cytokine responses in human infection with Mycobacterinin tuberculosis. Infect Immun 1995; 63: 3231-3234.
9. Law K F, Weiden M, Harkin T, TchouAVong K, Chi C, Rom W N. Increased release of IL-lß, IL-6, and TNF-a by bronchoalveolar cells lavaged from involved sites in pulmonary tuberculosis. Am J Respir Crit Care Med 1996; 153: 799-804.
10. Kindle V, Sappino A -P, Gran G E, Piguet P-F, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56: 731-740.
11. Lopez-Ramirez G M, Rom W N, Bonk S J, Cronstein B N, Reibman J. Mycobacterium tuberculosis alters expression of adhesion molecules on monocytic cells. Infect Immun 1994; 62:2515-2520.
12. Chang J C, Wysocki A, Tchou-Wong K M, Moskowitz N, Zhang Y, Rom W N. Effect of Mycobacterium tuberculosis and its components on macrophages and the release of matrix metalloproteinases. Thorax 1996; 51: 306-311.
13. Aderka D, Le J M, Vilcek J. IL-6 inhibits lipopolysaccharideinduced tumor necrosis factor production in cultured human monocytes, U937 cells in mice. J Immunol 1989; 143: 3517-3523.
14. Akira S, Isshiki H, Sugita T, et al. A nuclear factor IL-6 expression (NFIL6) is a member of the CEBP family. EMBO J 1990; 9: 1897-1906.
15. Zhang Y, Broser M, Rom W N. Activation of the interleukin6 gene by Mycobacterium tuberculosis or lipopolysaccharide is mediated by NF-IL6 and NF-KB. Proc Natl Acad Sci USA 1994; 91:2225-2229.
16. Tchou-Wong K M, Tanabe O, Chi C, Yie T A, Rom W N. Activation of NF-KB in Mycobacterium tuberculosis-induced interleukin-2 receptor expression in mononuclear phagocytes. Am J Respir Crit Care Med, 1999; 159: 1323-1329.
17. Robinson D S, Ying S, Taylor I K, et al. Evidence for the Thl-Iike bronchoalveolar T-cell subset and predominance of interferon-gamma gene activation in pulmonary tuberculosis. Am J Respir Crit Care Med 1994; 149: 989-993.
18. Condos R, Rom W N, Liu Y M, Schluger N W. Local immune responses correlate with presentation and outcome in tuberculosis. Am J Respir Crit Care Med 1998; 157: 729-735.
19. Condos R, Rom W N, Schluger N W. Treatment of multidrugresistant pulmonary tuberculosis with interferon-γ via aerosol. Lancet 1997; 349: 1513-1515.
20. Jones B E, Young M M Y, Antoniskis D, Davidson P T, Kramer F, Barnes P F. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993; 148: 1292-1297.
21. Lucas S, Nelson A M. Pathogenesis of tuberculosis in human immunodeficiency virus infected people. In: Bloom B R, ed. Tuberculosis: pathogenesis, protection, and control. Washington, DC: American Society for Microbiology, 1994: pp 503-514.
22. Flynn J L, Goldstein M M, Chan J, et al. Tumor necrosis factor-a is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995; 2: 562-572.
23. Cooper A M, Dalton D K, Stewart T A, Griffin J P, Russell D G, Orme I M. Disseminated tuberculosis in interferon-γ gene-disrupted mice. J Exp Med 1993; 178: 2243-2247.
24. Kamijo R, Le J, Shapiro D, et al. Mice that lack the interferon-γ receptor have profoundly altered responses to infection with Bacillus Calmette-Guerin and subsequent challenge with lipopolysaccharide. J Exp Med 1993; 173: 1435-1440.
25. Holland S M, Eisenstein E M, Kuhns D B, et al. Treatment of refractory disseminated nontuberculoiis mycobacterial infection with interferon gamma. N Engl J Med 1994; 330: 1348-1355.
26. Haas D W, Des Prez R M. Tuberculosis and acquired immunodeficiency syndrome: a historical perspective on recent developments. Am J Med 1994; 96: 439-450.
27. Whalen C, Horsburgh C R, Horn D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995; 151: 129-135.
28. Park M M, Davis A, Schluger N, Cohen H, Rom W N. Outcome of MDR-TB patients, 1983-1993: prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996; 153:317-324.
29. Zhang Y, Nakata K, Weiden M, Rom W. Mycobacteriiim tuberculosis enhances HIV-1 replication by transcriptional activation at the long terminal repeat. J Clin Invest 1995; 95: 2324-2331.
30. Nakata K, Weiden M, Harkin T, Ho D, Rom W N. Low copy number and limited variability of proviral DNA in alveolar macrophages from HIV-1 infected patients: evidence for genetic differences in HIV-1 between lung and blood macrophage populations. Mol Med 1995; 1: 744-757.
31. van der Broek M, Muller U, Huang S, Zinkernagel R, Aguet M. Immune defense in mice lacking type I and/or type II interferon receptors. Immunol Rev 1995; 148: 5-18.
32. Eloranta M, Sandberg K, Alm G. The interferon responses of mice to herpes simplex virus studied at the blood and tissue level in vitro and in vivo. Scan J Immunol 1996; 43: 355-360.
33. Edery I, Petryshyn R, Sonenberg N. Activation of doublestranded RNA-dependent kinase (dsl) by the TAR region of HIV-1 mRNA: a novel translational control mechanism. Cell 1989; 56: 303-312.
34. Der S, Lau A. Involvement of the double-stranded-RNAdependent kinase PKR in interferon expression and interferonmediated antiviral activity. Proc Natl Acad Sci USA 1995; 92: 8841-8845.
35. Honda Y, Rogers L, Nakata K, et al. Type I interferon induces inhibitory 16 kDa C/EBP-ß repressing the HIV-1 LTR in macrophages: pulmonary tuberculosis alters C/EBP expression enhancing HIV-1 replication.] Exp Med 1998; 188: 1255-1265.
36. Hamilton J A, Geneviève W A, Kola I, Hertzog P J. Endogenous interferon-/ suppresses colony-stimulating factor (CSF-1 ) stimulated macrophage DNA synthesis and mediates inhibitory effects of LPS and TNF-a. J Immunol 1996; 156: 2553-2557.
37. Zhang Y, Doerfler M, Lee T C, Guillemin B, Rom W N. Mechanisms of stimulation of interleukin-lß and tumor necrosis factor-a by Mycobacteriiim tuberculosis and its components. J Clin Invest 1993; 91: 2076-2083.
38. Kornbluth R S, Oh P S, Munis J R, Cleveland P H, Richman D D. IFNs and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro. J Exp Med 1989; 169: 1137-1151.
39. Bernstein M S, Tong-Starksen S E, Locksley R M. Activation of human monocyte-derived macrophages with lipopolysaccharide decreases human immunodeficiency virus replication at the level of gene expression. J Clin Invest 1991; 88: 540-545.
40. Giosue S, Casarini M, Alemanno L, et al. Effects of aerosolized interferon-a in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1998; 158: 1156-1162.
41. Khan N, Pulford A, Farquharson M, et al. The distribution of immunoreactive imerferon-alpha in normal human tissues. Immtinol 1989; 66: 201-206.
42. Hwang S, Herzog P J, Holland K, et al. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferon ex and ßalters macrophage responses. Proc Natl Acad Sci USA 1995; 92: 11284-11288.
43. Nakata K, Rom \V, Honda Y, et al. Al. tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am J Respir Crit Care Med 1997; 155: 996-1003.
44. Gessani S, Testa U, Varano B, et al. Enhanced production of LPS-induced cytokines during differentiation of human monocytes to macrophages: role of LPS receptors. J Immunol 1993; 151:3758-3766.
45. Lau A, Read S, Williams B. Downregulation of interferon alpha but not gamma receptor expression in vivo in the acquired immunodeficiency syndrome. J Clin Invest 1988; 82: 1415-1421.
46. Stancovski I, Baltimore D. NF-KB activation: the I KB kinase revealed? Cell 1997; 91: 299-302.
47. Goletti D, Kinter A L, Biswas P, Bende S M, Poli G, Fauci A S. Effect of cellular differentiation on cytokine-induced expression of human immunodeficiency virus in chronically infected promonocytic cells: dissociation of cellular differentiation and viral expression. J Virol 1995; 69: 2540-2546.
48. Rich E, Chen I, Zack J, Leonard M, O'Brien \V. Increased susceptibility of differentiated mononuclear phagocytes to productive infection with human immunodeficiency virus-1. J Clin Invest 1992; 89: 176-183.
49. Shattock R J, Friedland J, Groffin G. Phagocytosis of Alycobactemun tuberculosis modulates human immunodeficiency virus replication in human monocytic cells. J Gen Virol 1994; 75: 849-856.
50. Lederman M, Georges D, Kusner D, Mudido P, Giam C, Toossi Z. Mycobacteritim tuberculosis and its purified protein derivative activate expression of human immunodeficiency virus. J Aquir Immun Deficiency Syndrome 1994; 7: 727-733.
51. Tesmer V M, Rajadhyaksha A, Babin J, Bina M. NF IL-6mediated transcriptional activation of the long terminal repeat of the human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993; 90: 7298-7303.
52. Henderson A J, Calame K L. CCAAT/enhancer binding protein (C/EBP) sites are required for HIV-1 replication in primary macrophages but not CD4+ T cells. Proc Natl Acad Sci USA 1997; 94: 8714-8719.
53. Henderson A J, Zou X, Calame K. C/EBP proteins activate transcription from human immunodeficiency virus type 1 long terminal repeat in macrophages/monocytes. J Virol 1995; 69: 5337-5344.
54. Henderson A J, Connor R I, Calame K L. C/EBP activators are required for HIV-1 replication and proviral induction in monocyticcell lines. Immunity 1996; 5: 91-101.
55. Pope R M, Lentz A, Ness S A. C/EBPß regulation of the tumor necrosis factor a gene. J Clin Invest 1995; 94: 1449-1455.
56. Zhang Y. Rom \V N. Regulation of the interleukin-lß gene by mycobacterial components and lipopolysaccharide is mediated by two NF-IL6-like motifs. Mol Cell Biol 1993; 13: 3831-3837.
57. Screpanti I, Muisiani P, Bellavia D, et al. Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBPß-deficient mice. J Exp Med 1996; 186: 1561-1566.
58. Donovan R M, Bush C, Markowitz N, Baxa D, Saravolatz L. Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons. J Infect Dis 1996; 174: 401-403.
59. Ho D D. HIV-1 viremia and influenza. Lancet 1992; 339: 1549.
60. Lu W, Israel-Biet D. Virion concentration in bronchoalveolar lavage fluids of HIV-infected patients. Lancet 1993; 342: 298.
61. Stanley S K, Ostrowski MA, Justement J S, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type I. N Engl J Med 1996; 334: 1222-1230.